Guardant Health, Inc. (GH)
162.59
+4.71
(+2.98%)
USD |
NASDAQ |
Oct 20, 16:00
163.43
+0.84
(+0.52%)
Pre-Market: 08:15
Guardant Health Research and Development Expense (TTM) : 375.79M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 375.79M |
| March 31, 2026 | 366.71M |
| December 31, 2025 | 364.19M |
| September 30, 2025 | 359.47M |
| June 30, 2025 | 356.82M |
| March 31, 2025 | 352.47M |
| December 31, 2024 | 347.75M |
| September 30, 2024 | 343.42M |
| June 30, 2024 | 349.46M |
| March 31, 2024 | 356.22M |
| December 31, 2023 | 364.94M |
| September 30, 2023 | 379.74M |
| June 30, 2023 | 386.00M |
| March 31, 2023 | 381.40M |
| December 31, 2022 | 368.53M |
| September 30, 2022 | 337.55M |
| June 30, 2022 | 308.90M |
| March 31, 2022 | 287.37M |
| Date | Value |
|---|---|
| December 31, 2021 | 263.22M |
| September 30, 2021 | 230.48M |
| June 30, 2021 | 195.76M |
| March 31, 2021 | 168.35M |
| December 31, 2020 | 141.36M |
| September 30, 2020 | 126.96M |
| June 30, 2020 | 115.28M |
| March 31, 2020 | 98.49M |
| December 31, 2019 | 86.29M |
| September 30, 2019 | 77.07M |
| June 30, 2019 | 66.75M |
| March 31, 2019 | 58.78M |
| December 31, 2018 | 50.71M |
| September 30, 2018 | 42.18M |
| June 30, 2018 | 35.18M |
| March 31, 2018 | 29.12M |
| December 31, 2017 | 25.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Natera, Inc. | 787.38M |
| Quest Diagnostics, Inc. | -- |
| Labcorp Holdings, Inc. | -- |
| OPKO Health, Inc. | 125.22M |
| Psychemedics Corp. | -- |